Hemenway Trust Co LLC Has $1.31 Million Position in Novo Nordisk A/S (NYSE:NVO)

Hemenway Trust Co LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,956 shares of the company’s stock after selling 432 shares during the quarter. Hemenway Trust Co LLC’s holdings in Novo Nordisk A/S were worth $1,305,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in NVO. Russell Investments Group Ltd. lifted its stake in shares of Novo Nordisk A/S by 195.7% during the 1st quarter. Russell Investments Group Ltd. now owns 455,329 shares of the company’s stock worth $58,415,000 after buying an additional 301,361 shares during the last quarter. William Blair Investment Management LLC lifted its position in Novo Nordisk A/S by 2.3% during the first quarter. William Blair Investment Management LLC now owns 53,423 shares of the company’s stock worth $6,860,000 after acquiring an additional 1,185 shares during the last quarter. Cozad Asset Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 8.2% during the first quarter. Cozad Asset Management Inc. now owns 16,418 shares of the company’s stock worth $2,108,000 after acquiring an additional 1,248 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $80,000. Finally, TD Asset Management Inc increased its stake in shares of Novo Nordisk A/S by 10.9% during the first quarter. TD Asset Management Inc now owns 1,074,022 shares of the company’s stock worth $137,904,000 after purchasing an additional 105,523 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.2 %

Novo Nordisk A/S stock traded down $2.45 during trading hours on Tuesday, hitting $106.64. The stock had a trading volume of 546,361 shares, compared to its average volume of 4,425,818. The stock has a market cap of $478.55 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 1.48 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s 50 day simple moving average is $120.82 and its 200-day simple moving average is $130.22. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NVO shares. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.